共 12 条
[1]
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
[J].
JOURNAL OF CLINICAL ONCOLOGY,
2005, 23 (16)
:3676-3685
[2]
HABBEMA JDF, 1986, JNCI-J NATL CANCER I, V77, P317
[6]
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
[J].
PLOS ONE,
2016, 11 (06)